Up to $35 million from the Gates Foundation will support ProFound's use of its platform, datasets, and algorithms to identify new drug targets and biomarkers for preeclampsia and eclampsia

盖茨基金会将提供高达3,500万美元的资金，支持ProFound利用其平台、数据集和算法，为子痫前期和子痫识别新的药物靶点和生物标志物。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

,

，

Aug. 27, 2026

2026年8月27日

/PRNewswire/ -- ProFound Therapeutics, a Flagship Pioneering company harnessing the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced that it has received an investment commitment of up to $35 million from the Gates Foundation, including an initial investment of $20 million, to create new solutions for women's health.

/美通社/ -- ProFound Therapeutics 是一家隶属于 Flagship Pioneering 的公司，致力于利用扩展的人类蛋白质组开发针对多种疾病的首创药物。该公司今日宣布，已获得盖茨基金会高达 3,500 万美元的投资承诺（包括 2,000 万美元的初始投资），用于打造女性健康领域的新解决方案。

This investment supports its ProFoundry™ platform and agentic AI capabilities for the discovery of novel biomarkers and first-in-class protein drugs and drug targets for preeclampsia and eclampsia..

此项投资支持其ProFoundry™平台及智能体AI能力，用于发现先兆子痫和子痫的新型生物标志物、首创类蛋白质药物及药物靶点。

With this funding, ProFound Therapeutics will use its proprietary ProFoundry™ Platform to discover novel proteins from the expanded proteome that are expressed in placenta and serum derived from women with preeclampsia and eclampsia. By examining the causal biology of emerging targets, this work aims to support the identification of optimally validated biomarkers and targets for preeclampsia and eclampsia, as well as the creation of a novel preeclampsia/eclampsia-specific AI tool..

凭借这笔资金，ProFound Therapeutics 将利用其专有的 ProFoundry™ 平台，从扩展蛋白质组中发现由子痫前期和子痫患者胎盘及血清表达的新型蛋白质。通过深入研究新兴靶点的因果生物学机制，这项工作旨在支持识别经过充分验证的子痫前期和子痫生物标志物及靶点，并开发一种新型针对子痫前期/子痫的人工智能工具。

'Preeclampsia and eclampsia are devastating conditions for mothers and families across the globe, yet little is known about the underlying biology driving these diseases and therapeutic options remain limited,' said John Lepore, M.D., CEO of ProFound Therapeutics and Flagship Pioneering CEO-Partner.

“子痫前期和子痫对全球母亲和家庭造成毁灭性影响，然而人们对驱动这些疾病的潜在生物学机制知之甚少，治疗选择仍然有限。”ProFound Therapeutics 首席执行官兼 Flagship Pioneering 首席执行官合伙人约翰·莱波雷医学博士表示。

'The expanded proteome represents a vast and largely untapped resource for identifying novel protein drugs, drug targets, and biomarkers for diseases with significant unmet need. By systematically uncovering previously unknown proteins and unexplored biology, we are enabling a new generation of diagnostic and therapeutic possibilities.

扩展的蛋白质组代表着一个巨大且尚未充分开发的资源，可用于识别新型蛋白药物、药物靶点以及针对存在重大未满足需求的疾病的生物标志物。通过系统性地揭示此前未知的蛋白质和未被探索的生物学机制，我们正在开启新一代诊断和治疗的可能性。

This funding from the Gates Foundation gives us the opportunity to translate this scientific innovation into meaningful global impact for women affected by these chronically underserved conditions.'.

盖茨基金会的这笔资助使我们有机会将这一科学创新转化为对受这些长期服务不足疾病影响的女性具有实质意义的全球影响。

Herbert 'Skip' Virgin, M.D., Ph.D., Head of AI-Enabled Cures Frontier Accelerator at the Gates Foundation, added, 'Conditions like preeclampsia and eclampsia remain chronically underdiagnosed and undertreated. With only about 1% of global healthcare R&D directed toward female-specific conditions beyond cancer, promising treatments can take over a decade to reach the women who need them most.

盖茨基金会人工智能赋能疗法前沿加速器负责人赫伯特·“斯基普”·维珍医学博士、哲学博士补充道：“子痫前期和子痫等病症长期以来一直存在诊断不足和治疗不足的问题。由于全球仅有约1%的医疗健康研发资金投向癌症以外的女性特有疾病，有前景的治疗方法往往需要十多年才能惠及最迫切需要的女性患者。”

Closing that gap is a core commitment of the Gates Foundation. We are excited to support ProFound Therapeutics and its innovative approach to maternal health, utilizing proprietary knowledge of the expanded human proteome with agentic AI to generate new biological insights and targets for therapeutics and biomarkers that can be translated into real patient impact.'.

缩小这一差距是盖茨基金会的核心承诺。我们很高兴支持ProFound Therapeutics及其在孕产妇健康领域的创新方法，该方法利用对人类扩展蛋白质组的专有知识，结合代理式人工智能，生成新的生物学见解以及可转化为实际患者获益的治疗靶点和生物标志物。

About ProFound™ Therapeutics

关于 ProFound™ Therapeutics

ProFound Therapeutics is discovering proteins hidden within the expanded human proteome to uncover novel protein drugs and drug targets. The company's ProFoundry™ Platform uses state-of-the-art protein detection technologies, computational methods and high-throughput experimental assays to systematically identify novel proteins and define their connectivity, functionality, and roles in health and disease.

ProFound Therapeutics 正在从扩展的人类蛋白质组中发现隐藏的蛋白质，以揭示新型蛋白质药物和药物靶点。该公司的 ProFoundry™ 平台采用最先进的蛋白质检测技术、计算方法和高通量实验分析，系统性地鉴定新型蛋白质，并阐明其相互关联、功能以及在健康与疾病中的作用。

The result is the identification of a broad new class of therapeutic targets that is leading to a portfolio of first-in-class medicines. ProFound Therapeutics was founded in 2020 by Flagship Labs, the innovation foundry of Flagship Pioneering. For more information, please visit .

这一成果催生了一类全新的广泛治疗靶点，并推动了一系列首创药物的研发。ProFound Therapeutics 由 Flagship Pioneering 旗下的创新孵化机构 Flagship Labs 于 2020 年创立。欲了解更多信息，请访问 。

www.profoundtx.com

www.profoundtx.com

SOURCE ProFound Therapeutics

来源：ProFound Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，附带

Request a Demo

申请演示